1ZIMMET P, SHAW J, ALBERTI K G. Preventing type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view [J]. Diabet Med, 2003,20(9) : 693 -702.
2陈新谦,金有豫,汤光.新编药物学[M].16版.北京:人民卫生出版社,2003:44.
3FONSECA V, ROSENSTOCK J, PATWARDHAN R , et al. Effect of metforrnin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial [ J ]. JAMA, 2000, 283 (13) : 1695 -1702.
4OWEN M R , DRAN E, HALESTRAP A P. Evidence that mefformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain [ J ]. Biochem J, 2000, 348 ( Pt3 ) : 607 - 614.
5JUNTTI-BERGGREN L,PIGON J, HELLSTROM P ,et al. Influence of acarbose on post-prandial insulin requirements in patients with Type 1 diabetes[J]. Diabetes Nutr Metab, 2000, 13 ( 1 ) : 7 - 12.
6Korykowski M.Thomas A.Reid Iet al.Glimepiride improve both first and second phase of insulin secretion in type 2 diabetes[J]. Diabetes Care, 2002,25( 9 ):1067.
7Muller G. The molecular mechanism of the insulinmimetic/sensitizing activity of the antidiabetic sulfonylurea drug amaryl[J]. Mol Med, 2000, 6 ( 11 ):.907- 933.
8Ong CR, Molyneaux LM, Constantino MI, et al. Longterm efficacy of metformin therapy in nonobese indi- viduals with type2 diabetes[J].Diabetes Care 2006. 29 ( 11 ):2361-2364.
